feed,title,long_url,short_url
Benzinga,"Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance",https://benzinga.com/analyst-ratings/analyst-color/24/08/40200109/rare-disease-focused-biomarin-narrows-sales-focus-cuts-cost-for-hemophilia-a-gene-t,https://da.gd/n8CbW
